1. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Issue 10160 (17th November 2018) Authors: Frias, Juan Pablo; Nauck, Michael A; Van, Joanna; Kutner, Mark E; Cui, Xuewei; Benson, Charles; Urva, Shweta; Gimeno, Ruth E; Milicevic, Zvonko; Robins, Deborah; Haupt, Axel Journal: Lancet Issue: Volume 392:Issue 10160(2018) Page Start: 2180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗